Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)
NCT07295223 · PHASE3 · COMPLETED · Sponsor: Instituto Mexicano del Seguro Social · Conditions: Acute Myocardial Infarction With ST
PR
By Priya Raman · Science Reporter
Nov 4 07:00 ETSource: ClinicalTrials.gov
From the source
Read at clinicaltrials.govEffect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)
NCT07295223 · PHASE3 · COMPLETED · Sponsor: Instituto Mexicano del Seguro Social · Conditions: Acute Myocardial Infarction With ST Elevation.
Source URL https://clinicaltrials.gov/study/NCT07295223
